___________________________________________________________ _______________________________________________________________
lentiviral and AAV programs stem from a broader belief that manufacturing experience should create measurable advantages for customers. Achieving those gains, however, necessitates more than capacity and process improvements. It depends on using knowledge accumulated over decades of work.
With more than three decades of viral vector development and manufacturing behind it, OXB is increasingly focusing on how that knowledge can be applied across future programs.“ The challenge is no longer generating information. It’ s making better use of the information already available. Over more than 30 years, we’ ve built a significant body of knowledge through development and manufacturing activities, and we’ re paying particular attention to how we can leverage the huge amount of data we’ ve generated across projects.”
As OXB takes on more programs, the opportunity lies in applying lessons from previous work rather than starting from the beginning each time. The next leverage may come not from new infrastructure, but from how effectively OXB can draw on what it has already learned.“ We’ re placing a strong focus on data analysis and how we can make better use of the vast amount of data we’ ve generated across our projects.” The objective is practical. If previous programs have already
We looked at the pros and cons of buying versus building. Acquiring the facility was faster than continuing the expansion in Bedford, and we weren’ t just buying a shell. We were bringing in an experienced team that was already operating there
generated useful insights, teams should be able to build on that foundation rather than recreate it.
Much of OXB’ s recent growth has been driven by manufacturing, but investment in the underlying science has not slowed. OXB has continued investing in the technologies that will shape future therapies. One area receiving sustained attention is in vivo cell and gene therapy, where it continues to invest heavily in in vivo platform development for in vivo CAR-T therapies.
Work on expression systems, promoters, and vector design remains an active part of OXB’ s development strategy, reflecting a belief that manufacturing and innovation must continue to evolve together. OXB wants higher yields without sacrificing vector quality.“ It’ s not just about productivity. We’ re equally focused on the quality of the vector we deliver in the end,” states Sébastien.
The market has moved too. When Sébastien joined the company, oncology programs and ex vivo CAR-T therapies
124